Market Overview

GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV

Related GSK
GlaxoSmithKline, 23andMe Partner On DNA Data In Drug Development
Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile
Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point (Seeking Alpha)
Related GILD
The Highs And Lows Of Earnings Season Dominate July's IMX Results
Investor Movement Index July Summary
Stanley Druckenmiller Bets on Facebook and Oil (GuruFocus)

GlaxoSmithKline plc GSK has announced the start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV. ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer PFE, said that the phase III study, HPTN 084, will evaluate long-acting cabotegravir monotherapy for the prevention of HIV infection in sexually active women.

ViiV Healthcare is conducting the study under a public private funding collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation. While NIAID, part of the National Institutes of Health (NIH), is sponsoring the study, ViiV Healthcare and Gilead GILD are providing the medicines. The study will enrol more than 3,000 women between the age of 18 and 45 from sub-Saharan African countries.

In order to prevent HIV infection, uninfected people, at present, use oral anti-retroviral medication, which needs to be taken every day. Compared to these, cabotegravir injections will be administered every two months, if approved

Glaxo's shares have declined 9% this year so far, underperforming the 16.2% increase witnessed by the industry.

ViiV Healthcare is already conducting a HPTN 083 study on cabotegravir in HIV-uninfected men and transgender women who have sex with men, also under co-funding with NIAID. Meanwhile, cabotegravir is also being evaluated in three late stage studies as a two drug regimen with Johnson & Johnson's JNJ Edurant/rilpivirine, with the third study initiation announced earlier this week.

Last week Glaxo and partner J&J announced FDA approval of the first dual treatment for HIV, Juluca (Tivicay/dolutegravir + Edurant/rilpivirine). Juluca has been developed under a partnership between ViiV Healthcare and Janssen.

HIV has been a key therapeutic area for Glaxo. Its two new HIV drugs, Tivicay and Triumeq have been recording consistently strong sales while gaining market share. Glaxo's HIV sales rose 16% at constant exchange rate in the first nine months of 2017. Meanwhile, a significant portion of its R&D expenditures goes toward developing HIV medicines to treat/prevent HIV.

Glaxohas a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Pfizer, Inc. (NYSE: PFE): Free Stock Analysis Report
Johnson & Johnson (NYSE: JNJ): Free Stock Analysis Report
GlaxoSmithKline PLC (NYSE: GSK): Free Stock Analysis Report
Gilead Sciences, Inc. (NASDAQ: GILD): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: contributor contributorsBiotech News FDA General


Related Articles (GILD + GSK)

View Comments and Join the Discussion!

'Watch' Could Add $500 Million To Facebook Sales

Pembina Pipeline Announces Growth Projects, Sets 2018 Capex